Featured Research

from universities, journals, and other organizations

A human hepatoma multidrug resistant cell line in vitro

Date:
May 12, 2010
Source:
World Journal of Gastroenterology
Summary:
Drug resistance is still a major impediment in the treatment of cancer. A recent study from China describes the establishment of a multidrug resistant (MDR) cell line, SK-Hep-1/CDDP, which can be used as an in vivo model to investigate the molecular mechanisms involved in MDR-related genes of hepatocarcinoma and to explore the targeted approaches for overcoming MDR in tumor cells.

Hepatocellular carcinoma (HCC) responds poorly to chemotherapy owing to MDR. Recent studies have shown the tumors derived from the colon, kidney, or adrenal cortex, and HCC exhibited overexpression of MDR1/P-gp. This overexpression results in a primary MDR phenotype of these cancers. Tumor derived cell lines are one of the most important tools for investigation of the biological mechanisms directly leading to drug resistance in patients. Today, the experimental search for drug resistant mechanisms that are clinically relevant targets whose circumvention can improve cancer therapy is still ongoing.

A research, lead by Professor Ling and his colleagues in the Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, has recently been published on May 14, 2010 in the World Journal of Gastroenterology, to represent models for investigating MDR in human HCC. Analysis of novel chemotherapy-resistant cell lines may duplicate the treatment conditions used in vivo.

The new MDR cell line, SK-Hep1/CDDP, can be used as an in vitro model to elucidate the biological mechanisms of MDR in hepatoma, from delineating the process of carcinogenesis through to testing new therapeutic agents. SK-Hep1/CDDP cells can also be used to explore targeted approaches for improving MDR cancer therapy.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Zhou Y, Ling XL, Li SW, Li XQ, Yan B. Establishment of a human hepatoma multidrug resistant cell line in vitro. World Journal of Gastroenterology, 2010; 16 (18): 2291 DOI: 10.3748/wjg.v16.i18.2291

Cite This Page:

World Journal of Gastroenterology. "A human hepatoma multidrug resistant cell line in vitro." ScienceDaily. ScienceDaily, 12 May 2010. <www.sciencedaily.com/releases/2010/05/100512112145.htm>.
World Journal of Gastroenterology. (2010, May 12). A human hepatoma multidrug resistant cell line in vitro. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/05/100512112145.htm
World Journal of Gastroenterology. "A human hepatoma multidrug resistant cell line in vitro." ScienceDaily. www.sciencedaily.com/releases/2010/05/100512112145.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins